Incidence, Disease Course, and Medical Treatment of a Danish Population-Based Cohort of Very Early-Onset Inflammatory Bowel Disease
Table 4
Distribution of medical treatment among patients with VEO-IBD (stratified by diagnosis, period of diagnosis, and years after diagnosis) during follow-up.
Diagnosis 2015-2020
Diagnosis before 2015
CD
UC
IBDU
CD
UC
IBDU
()
()
()
()
()
()
SCT
%
%
%
%
%
%
0-1 yr after diagnosis
Yes
3
75.0
3
30.0
2
40.0
7
100
12
92.3
0
0
End of follow-up
0
0
0
0
0
0
0
0
0
0
0
0
1-3 yrs after diagnosis
Yes
1
25.0
3
30.0
1
20.0
6
85.7
8
61.5
1
100
End- f follow-up
0
0
3
30.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
1
25.0
0
0
0
0
2
28.6
6
46.15
0
0
End of follow-up
2
50.0
8
80.0
5
100
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
0
0
0
0
0
2
28.6
3
23.1
1
100
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
5-ASA
0-1 yr after diagnosis
Yes
1
25.0
9
90.0
4
80.0
5
71.4
12
92.3
1
100
End of follow-up
0
0
0
0
0
0
0
0
2
15.4
0
0
1-3 yrs after diagnosis
Yes
2
50.0
4
40.0
1
20.0
5
71.4
10
76.7
1
100
End of follow-up
0
0
3
30.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
0
2
20.0
0
4
57.1
10
76.7
1
100
End of follow-up
2
50.0
8
80.0
5
100
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
0
0
0
0
0
3
42.9
11
84.6
1
100
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
Immunomodulators
0-1 yr after diagnosis
Yes
3
75.0
5
50.0
2
40.0
5
71.4
7
53.8
0
0
End of follow-up
0
0
0
0
0
0
0
0
0
0
0
0
1-3 yrs after diagnosis
Yes
1
25.0
4
40.0
2
40.0
7
100
7
53.8
1
100
End of follow-up
0
0
3
30.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
1
25.0
1
10.0
0
0
6
85.7
8
61.5
1
100
End of follow-up
2
50.0
8
80.0
5
100
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
100
0
0
0
0
6
85.7
8
61.5
1
100
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
Anti-TNF-alpha
0-1 yr after diagnosis
Yes
3
75.0
5
50.0
0
0
2
28.6
4
30.8
0
0
End of follow-up
0
0
0
0
0
0
0
0
0
0
0
0
1-3 yrs after diagnosis
Yes
3
75.0
2
40.0
1
20.0
3
42.3
2
15.4
0
0
End of follow-up
0
0
3
60.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
2
50.0
0
0
0
0
4
57.1
3
23.1
0
0
End of follow-up
2
50.0
8
80.0
5
100
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
0
0
0
0
0
4
57.1
5
38.5
0
0
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
Vedolizumab, (%)
0-1 yr after diagnosis
Yes
0
0
2
20.0
0
0
0
0
0
0
0
0
End of follow-up
0
0
0
0
0
0
0
0
0
0
0
0
1-3 yrs after diagnosis
Yes
0
0
2
40.0
0
0
0
0
0
0
0
0
End of follow-up
0
0
3
60.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
0
0
0
0
0
0
0
0
1
7.7
0
0
End of follow-up
2
50.0
8
80.0
5
100
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
0
0
0
0
0
0
0
2
15.4
0
0
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
Operation
0-1 yr after diagnosis
Yes
0
0
1
10.0
0
0
0
0
2
15.4
0
0
End of follow-up
0
0
0
0
0
0
0
0
0
0
0
0
1-3 yrs after diagnosis
Yes
0
0
0
0
0
0
0
0
0
0
0
0
End of follow-up
0
0
3
30.0
3
60.0
0
0
2
15.4
0
0
3-5 yrs after diagnosis
Yes
0
0
0
0
0
0
0
0
0
0
0
0
End of follow-up
2
50.0
8
80.0
5
0
0
0
2
15.4
0
0
>5 yrs after diagnosis
Yes
0
0
0
0
0
0
0
0
0
0
0
0
End of follow-up
4
100
10
100
5
100
0
0
2
15.4
0
0
5-ASA: 5-aminosalicylic acid; TNF: tumor necrosis factor; SCT: systemic corticoid treatment; yrs: years; IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; IBDU: IBD unspecified; VEO: very early-onset.End of follow-up reached before the specific period.
